Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03166189
Other study ID # MSC-001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 20, 2017
Est. completion date December 28, 2019

Study information

Verified date December 2019
Source D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigators will examine safety and efficiency of the cell product of autologous bone marrow-derived mesenchymal stem cells (MSC) for patients with repeated IVF failures and hypoplastic or/and fibrosis process of endometrium


Description:

Sixty patients eligible for the study will be divided to two groups (experimental and control) according to randomization (envelope) procedure in 1:1 ratio.

For patients of the main group bone marrow stem cells will be extracted from the crest of the ilium using standard methodology. After extraction and cultivation final product of autologous bone marrow-derived mesenchymal stem cells will be transplanted to endometrial cavity on menstrual cycle day 5-6. Meanwhile patients will receive three cycles of hormonal replacement therapy (4 mg Progynova (Bayer Pharma, Germany) daily on menstrual cycle day 5-25 in combination with 20 mg Duphaston (Abbott Healthcare Products, B.V., Netherlands) daily from day 15 to day 25. On day 20 of hormonal replacement therapy (HRT) of the last (third) cycle Pipelle-biopsy of endometrium will be performed. Obtained material will be analyzed by immunohistochemistry with the assessment of estrogen and progesterone receptors, VEGFa, GM-CSF, CD133+, CD34 and CD56. Ultrasound characteristics of endometrial quality will be registered on day 9-10 and day 19-21 of every cycle. When morphological and echographic parameters of endometrium are found satisfactory for embryo transfer, the HRT for endometrial preparation for frozen/thawed embryo transfer cycle will be initiated. If acceptable endometrial characteristics are not achieved, patients could be offered to undergo repeated (not more than 3) transplantation of MSC procedures.

Control group will receive three standard cycles of HRT following hysteroscopy before frozen/thawed embryo transfer. If endometrial characteristics are found unsatisfactory, gestational surrogacy might be offered.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date December 28, 2019
Est. primary completion date March 16, 2019
Accepts healthy volunteers No
Gender Female
Age group 21 Years to 44 Years
Eligibility Inclusion Criteria:

- Repeated IVF attempts with high and good quality embryo transfer in fresh and frozen IVF cycles;

- Age 20-44 years;

- Endometrial thickness less than 6 mm in 2 or more of HRT cycles for endometrial preparation for embryo transfer

- Hysteroscopic evidence of fibrosis processes of uterine cavity with the absence of positive dynamics of HRT in 3 months following operation;

- Signed informed consent.

Exclusion Criteria:

- Contraindication for pregnancy;

- Absence of cryopreserved embryos, stored at clinic's cryobank;

- BMI > 30 kg/m2;

- Impaired carbohydrate metabolism according to glucose tolerance test;

- Thrombosis in anamnesis;

- Oncological diseases in anamnesis;

- Diagnosed inherited thrombophilia;

- Uterine fibroids of more than 4 cm or more than 2 fibroids of 2.5 cm diameter;

- Nodal form of adenomiosis;

- Ovarian cysts more than 4 cm in diameter.

Study Design


Intervention

Biological:
bone marrow-derived MSC and HRT
Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells Three cycles of HRT following MSC transplantation; Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle; Frozen/thawed embryo transfer 3-6 months after transplantation.
Other:
hormonal replacement therapy
standard treatment of hypoplastic endometrium or Asherman's syndrome: Three cycles of HRT preceding frozen/thawed embryo transfer; Frozen/thawed embryo transfer.

Locations

Country Name City State
Russian Federation D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology Saint Petersburg

Sponsors (1)

Lead Sponsor Collaborator
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of endometrial receptivity combination of endometrial thickness on ultrasound and immunohistochemistry of endometrium assessed at the biopsy day of the third cycle of HRT 3-6 month after randomization
Secondary Clinical pregnancy rate presence of intrauterine gestational sac at transvaginal ultrasound at 5-6 weeks of gestation or 5-6 weeks after starting the intervention; measured per frozen/thawed embryo transfer 3-4 weeks after embryo transfer
Secondary Treatment-Emergent Adverse Events Incidence of adverse events: side reactions, abdominal discomfort and patient's tolerance (Safety and Tolerability) 3-6 month after randomization
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting NCT05358483 - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Completed NCT03177538 - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Phase 4
Completed NCT03638856 - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy N/A
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn NCT04753736 - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC N/A
Completed NCT03349905 - Deferred Versus Fresh Embryo Transfers N/A
Completed NCT05076981 - Progesterone Levels During Ovulation and Luteal Phase
Completed NCT04096027 - Cabergoline Before or After Oocyte Collection for Follicular Resolution Phase 4
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Terminated NCT01933633 - Improved Fertility After Exercise in Overweight/Obese Women N/A
Terminated NCT01202643 - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF Phase 1/Phase 2
Completed NCT01202656 - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization) Phase 1/Phase 2
Completed NCT01408615 - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation NCT05698550 - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET Phase 3
Not yet recruiting NCT03910582 - Personalized FET in RIF Patients With Displaced Dating N/A
Completed NCT05440019 - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed NCT05130125 - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer